Skip to content

Study · In vitro (cells) · 2012

6 results

Sustained release of PTH(1-34) from PLGA microspheres suppresses osteoarthritis progression in rats.

Eswaramoorthy R, Chang CC, Wu SC, Wang GJ, Chang JK, Ho ML

Acta biomaterialia10 Mar 2012Cited by 69 (Europe PMC)

PMID22414620 (opens in a new tab)DOI10.1016/j.actbio.2012.03.015 (opens in a new tab)PepBankPUB-22414620
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In MC3T3E1 cells, PTH(1-34) released from PLGA microspheres elevated cAMP levels.

    In plain wordsIn cells, peptide released from PTH/PLGA microspheres increased cAMP levels.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCellular cAMP
    Study

    n: not reported in source

    MC3T3E1 cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The cAMP levels of MC3T3E1 cells were elevated in the response to released PTH(1-34) from PTH/PLGA microspheres, indicating that the released PTH(1-34) is bioactive.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In rat knee cartilage, intermittent PTH(1-34) and sustained-release PTH/PLGA similarly suppressed osteoarthritis-associated GAG loss.

    In plain wordsIn rats, intermittent peptide and sustained-release peptide similarly suppressed cartilage GAG loss caused by osteoarthritis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSuppression of GAG loss
    Study

    ratn: not reported in source

    Papain-induced knee osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Most importantly, intra-articular treatment with either PTH(1-34) (0.1-100 nM) 3 days/injection or PTH/PLGA microspheres (15 days/injection) for 5 weeks revealed the similar effect on suppressing papain-induced OA changes (decreasing GAG and Col II and increasing Col X) in rat knee cartilage.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 03AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In rat knee cartilage, intermittent PTH(1-34) and sustained-release PTH/PLGA similarly suppressed osteoarthritis-associated collagen II loss.

    In plain wordsIn rats, intermittent peptide and sustained-release peptide similarly suppressed collagen II loss caused by osteoarthritis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSuppression of collagen II loss
    Study

    ratn: not reported in source

    Papain-induced knee osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Most importantly, intra-articular treatment with either PTH(1-34) (0.1-100 nM) 3 days/injection or PTH/PLGA microspheres (15 days/injection) for 5 weeks revealed the similar effect on suppressing papain-induced OA changes (decreasing GAG and Col II and increasing Col X) in rat knee cartilage.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In rat knee cartilage, intermittent PTH(1-34) and sustained-release PTH/PLGA similarly suppressed osteoarthritis-associated collagen X increases.

    In plain wordsIn rats, intermittent peptide and sustained-release peptide similarly suppressed collagen X increases caused by osteoarthritis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSuppression of collagen X increase
    Study

    ratn: not reported in source

    Papain-induced knee osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Most importantly, intra-articular treatment with either PTH(1-34) (0.1-100 nM) 3 days/injection or PTH/PLGA microspheres (15 days/injection) for 5 weeks revealed the similar effect on suppressing papain-induced OA changes (decreasing GAG and Col II and increasing Col X) in rat knee cartilage.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 05LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cell-free)Other

    In laboratory characterization, PTH/PLGA microspheres had smooth surfaces and sizes in the reported range.

    In plain wordsIn lab tests, PTH/PLGA microspheres had smooth surfaces and a measured size range.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableMicrosphere morphology and size
    Study

    n: not reported in source

    PTH/PLGA microspheres
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Microsphere size
    51 to 127 μm
    PTH/PLGA microspheres

    Source sentences

    Summary
    Our results demonstrated that the surface of the PLGA microspheres was smooth, and the size of the microspheres was in the range of 51-127 μm.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 06LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cell-free)Pharmacokinetics

    In laboratory tests, PTH/PLGA microspheres released PTH(1-34) for 19 days within the reported concentration range.

    In plain wordsIn lab tests, PTH/PLGA microspheres released the peptide for 19 days.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSustained peptide release
    Study

    n: not reported in source

    PTH/PLGA microspheres
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Release duration
    19 days
    PTH/PLGA
    Released concentration
    0.01 to 100 nM
    37°C

    Source sentences

    Summary
    PTH/PLGA microspheres sustainably released PTH(1-34) for 19 days with a concentration range of 0.01-100 nM that covered the expected concentration of 10nM at 37°C.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.